RHUMBLINE ADVISERS

Position in ZYME — Zymeworks Inc.

CIK 1115418 BOSTON, MA

Position in ZYME

as of Mar 31, 2026 · filed May 12, 2026 Compact

Position Value

$1,887,990

-$99,872 QoQ

Shares Held

75,399

-0.1% QoQ

Ownership

0.103%

of shares outstanding

% of Portfolio

0.00%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Jun 2023

12 quarters on record

Voting authority Sole 34% Shared 0% None 66%

Healthcare · as of Mar 31, 2026

RHUMBLINE ADVISERS holds $1,237,848,251 across 287 Biotechnology names. ZYME ranks #91 (0.2% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	VRTX	Vertex Pharmaceuticals Inc / Ma	423,140	$188,948,935
2	REGN	Regeneron Pharmaceuticals, Inc.	157,781	$121,907,911
3	INCY	Incyte Corp	693,665	$65,287,749
4	ALNY	Alnylam Pharmaceuticals, Inc.	195,277	$64,611,300
5	INSM	INSMED Inc	272,615	$44,578,004
6	JAZZ	Jazz Pharmaceuticals plc	164,542	$31,106,665
7	EXEL	Exelixis, Inc.	723,931	$31,049,400
8	ROIV	Roivant Sciences Ltd.	1,113,266	$30,837,468

12 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$1,887,990	75,399	-0.1%	Shares	Sole	2026-05-12
2025-12-31	$1,987,862	75,498	-12.1%	Shares	Sole	2026-02-13
2025-09-30	$1,467,206	85,902	-0.2%	Shares	Sole	2025-11-06
2025-06-30	$1,080,341	86,083	+4.0%	Shares	Sole	2025-08-12
2025-03-31	$985,409	82,738	-20.3%	Shares	Sole	2025-05-29
2024-12-31	$1,520,744	103,876	+18.1%	Shares	Sole	2025-05-29
2024-09-30	$1,103,847	87,956	+1.2%	Shares	Sole	2024-11-12
2024-06-30	$739,621	86,912	+9.0%	Shares	Sole	2024-08-01
2024-03-31	$838,465	79,702	+2.7%	Shares	Sole	2024-05-09
2023-12-31	$806,232	77,597	+7.6%	Shares	Sole	2024-02-08
2023-09-30	$457,158	72,107	+3.0%	Shares	Sole	2023-11-09
2023-06-30	$604,920	70,014	—	Shares	Sole	2023-08-08
No filing history on record for this holder in this stock.